35,000
Participants
Start Date
January 1, 1996
Primary Completion Date
March 31, 2018
Study Completion Date
March 31, 2018
Exposure to one or more disease-modifying drug(s)(DMDs) used to treat MS
Individuals with MS exposed to one or more DMDs (beta-interferon, glatiramer acetate, natalizumab, fingolimod, dimethyl fumarate, teriflunomide, alemtuzumab, daclizumab or ocrelizumab; regardless of dose, frequency or duration of treatment) between 1st January 1996 and 31st March 2018 in five Canadian provinces.
University of Manitoba
OTHER
Dalhousie University
OTHER
University of Saskatchewan
OTHER
Alberta Health services
OTHER
University of Alberta
OTHER
University of British Columbia
OTHER